Last reviewed · How we verify

Vasoactive drug therapies

Gruppo Italiano Multidisciplinare per lo Studio della Sincope · Phase 3 active Small molecule

Vasoactive drug therapies is a Vasoactive agent / Sympathomimetic Small molecule drug developed by Gruppo Italiano Multidisciplinare per lo Studio della Sincope. It is currently in Phase 3 development for Syncope prevention and management (vasovagal syncope, orthostatic hypotension). Also known as: Antihypertensive, Nitrates, Alpha-antagonists, Diuretics.

Vasoactive drug therapies work by modulating vascular tone and blood pressure through sympathomimetic or vasodilatory mechanisms to prevent syncope and improve cardiovascular stability.

Vasoactive drug therapies work by modulating vascular tone and blood pressure through sympathomimetic or vasodilatory mechanisms to prevent syncope and improve cardiovascular stability. Used for Syncope prevention and management (vasovagal syncope, orthostatic hypotension).

At a glance

Generic nameVasoactive drug therapies
Also known asAntihypertensive, Nitrates, Alpha-antagonists, Diuretics, Neuroleptic antidepressant
SponsorGruppo Italiano Multidisciplinare per lo Studio della Sincope
Drug classVasoactive agent / Sympathomimetic
ModalitySmall molecule
Therapeutic areaCardiovascular
PhasePhase 3

Mechanism of action

Vasoactive agents increase peripheral vascular resistance and/or cardiac output to maintain adequate cerebral perfusion pressure, thereby preventing the sudden drops in blood pressure that lead to syncope. These drugs may act through alpha-adrenergic stimulation, beta-adrenergic effects, or direct vasodilation depending on the specific agent used. In the context of syncope management, they are typically employed to counteract vasovagal or orthostatic mechanisms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Vasoactive drug therapies

What is Vasoactive drug therapies?

Vasoactive drug therapies is a Vasoactive agent / Sympathomimetic drug developed by Gruppo Italiano Multidisciplinare per lo Studio della Sincope, indicated for Syncope prevention and management (vasovagal syncope, orthostatic hypotension).

How does Vasoactive drug therapies work?

Vasoactive drug therapies work by modulating vascular tone and blood pressure through sympathomimetic or vasodilatory mechanisms to prevent syncope and improve cardiovascular stability.

What is Vasoactive drug therapies used for?

Vasoactive drug therapies is indicated for Syncope prevention and management (vasovagal syncope, orthostatic hypotension).

Who makes Vasoactive drug therapies?

Vasoactive drug therapies is developed by Gruppo Italiano Multidisciplinare per lo Studio della Sincope (see full Gruppo Italiano Multidisciplinare per lo Studio della Sincope pipeline at /company/gruppo-italiano-multidisciplinare-per-lo-studio-della-sincope).

Is Vasoactive drug therapies also known as anything else?

Vasoactive drug therapies is also known as Antihypertensive, Nitrates, Alpha-antagonists, Diuretics, Neuroleptic antidepressant.

What drug class is Vasoactive drug therapies in?

Vasoactive drug therapies belongs to the Vasoactive agent / Sympathomimetic class. See all Vasoactive agent / Sympathomimetic drugs at /class/vasoactive-agent-sympathomimetic.

What development phase is Vasoactive drug therapies in?

Vasoactive drug therapies is in Phase 3.

What are the side effects of Vasoactive drug therapies?

Common side effects of Vasoactive drug therapies include Hypertension, Tachycardia, Tremor, Anxiety, Headache.

Related